Method for screening immune modulator
AssigneeImagene Co., Ltd.
InventorsSung-Hoon Kim, Jung-Min Han
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for screening an immune modulator. More specifically, disclosed is a method of screening an immune modulator, an anticancer agent and an agent for treating autoimmune diseases, which regulate the cell surface expression level of gp96, using the binding of the region of amino acids 54-192 of AIMP1 to the region of amino acids 699-799 of AIMP1, set forth in SEQ ID NO: 18. Also disclosed is a method of diagnosing autoimmune diseases using the binding.
Claims12
A method for screening an immune modulator, the method comprising the steps of:
- (a) contacting a test agent with an isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 4;
- and
- (b) testing whether the test agent binds to the isolated polypeptide.
A method for screening an immune modulator, the method comprising the steps of:
- (a) contacting a test agent with a cell or tissue expressing an isolated polypeptide, comprising an amino acid sequence set forth in SEQ ID NO:
- 4, and an isolated polypeptide, comprising an amino acid sequence set forth in SEQ ID NO:
- 18;
- and
- (b) detecting a change in the cell surface expression level of gp96 in the cell or tissue contacted with the test agent relative to the cell surface expression level of gp96 in a cell or tissue not contacted with the test agent.
A method for screening an anticancer agent, the method comprising the steps of:
- (a) contacting a test agent with an isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 4;
- (b) testing whether the test agent binds to the isolated polypeptide;
- (c) administering the test agent to a cancer cell or a cancer animal model;
- and
- (d) detecting a change in the progression of cancer in the cancer cell or cancer animal model administered with the test agent.
A method for screening an anticancer agent, the method comprising the steps of:
- (a) contacting a test agent with a cell or tissue expressing a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 4;
- (b) testing whether the cell surface expression level of gp96 in the cell or tissue contacted with the test agent is increased compared to the cell surface expression level of gp96 in a cell not contacted with the test agent;
- (c) administering the test agent to a cancer cell or a cancer animal model;
- and
- (d) detecting a change in the progression of cancer in the cancer cell or cancer animal model administered with the test agent.
A method for screening an agent for treating autoimmune diseases, the method comprising the steps of:
- (a) contacting a test agent with an isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 18;
- (b) testing whether the test agent binds to the isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 18;
- (c) administering the test agent to an immune cell or an autoimmune disease animal model;
- and
- (d) measuring the degree of immune suppression in the immune cell or autoimmune disease model administered with the test agent.
A method for screening an agent for treating autoimmune diseases, the method comprising the steps of:
- (a) contacting a test agent with a cell or tissue expressing an isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 18;
- (b) testing whether the cell surface expression level of gp96 in the cell or tissue contacted with the test agent is decreased compared to the cell surface expression level of gp96 in a cell not contacted with the test agent;
- (c) administering the test agent to an immune cell or an autoimmune disease animal model;
- and
- (d) measuring the degree of immune suppression in the immune cell or autoimmune disease model administered with the test agent.
A composition for diagnosing autoimmune diseases, comprising an antibody specific for an AIMP1 protein.
A method for diagnosing autoimmune diseases, the method comprising the steps of:
- (a) contacting an antibody specific for an AIMP1 protein with a detection sample;
- (b) forming an antigen-antibody complex in the detection sample;
- and
- (c) comparing the formation of the antigen-antibody complex with that in a control group.
Dependencies are inferred from the claim text.